CAPS Stock UPDATES Capstone Therapeutics Corp (CAPS) 0.2350 10/23/2014
Post# of 273217
Capstone Therapeutics, Inc. - "AEM-28 Drug Class May Serve Larger Cardiovascular Markets"
ACCESSWIRE - Tue Oct 07, 7:51AM CDT
New York, NY / October 7, 2014 / Capstone Therapeutics (OTCQB: CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and Principal Executive Officer, John Holliman, III. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Capstone Therapeutics Corp. Announces Digital Corporate Communication Channels
GlobeNewswire - Fri Sep 05, 12:09PM CDT
Capstone Therapeutics Corp. (OTCQB:CAPS) (the "Company" or "Capstone Therapeutics" , a clinical stage biotechnology company developing a family of new peptide drugs, announced today its suite of online corporate communication channels to maintain on-going direct communication with stakeholders. The Company has launched official portals on social media channels including Facebook, Twitter, Google+ and The Chairman's Blog.
Capstone Therapeutics, Inc. - "A New Class of Cardiovascular Drug"
ACCESSWIRE - Fri Sep 05, 7:48AM CDT
New York, NY / September 5, 2014 / Capstone Therapeutics (OTCQB: CAPS) today published a new blog post on The Chairman's Blog, written by the Company's Executive Chairman and Principal Executive Officer, Jock Holliman. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals
GlobeNewswire - Tue Sep 02, 8:57AM CDT
Capstone Therapeutics (OTCQB:CAPS) ("the Company" and its joint venture affiliate, LipimetiX Development, LLC ("JV" , announced today the completion of dosing and patient follow-up for its investigational AEM-28 (Apo E mimetic peptide) Phase 1a human clinical trial in cholesterol and lipid reduction. The Medical Safety Committee, reviewing all safety-related aspects of the clinical trial, observed an acceptable safety profile. As a first-in-man study, the primary endpoint was safety; yet, biomarker efficacy measurements analyzing pharmacodynamics yielded trends favoring AEM-28 versus placebo in multiple cholesterol and lipid endpoints.
Capstone Therapeutics Will Provide an Operating Update and Announces Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 8:05AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , today will hold a conference call and webcast to provide an operating update and announced financial results for the second quarter 2014.
Capstone Therapeutics Announces Second Quarter 2014 Financial Results and Operating Update Conference Call
GlobeNewswire - Wed Aug 06, 9:00AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , will hold a conference call and webcast on Thursday, August 14, 2014 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning August 14, 2014 at 7:30 pm EDT until midnight August 17, 2014, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 81563431.
Capstone Therapeutics Announces Operating Update Conference Call, Planned Initiation of AEM-28 Phase 1 Study and Fiscal Year 2013 Financial Results
GlobeNewswire - Thu Mar 27, 9:29AM CDT
Capstone Therapeutics (OTCQB:CAPS) ("the Company" and its joint venture affiliate, LipimetiX Development, LLC ("JV" , today will hold a conference call and webcast to provide an operating update, discuss the start of AEM-28 Phase 1 clinical studies and report financial results for the fiscal year 2013.
Capstone Therapeutics Announces Operating Update Conference Call
GlobeNewswire - Mon Mar 24, 1:30PM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , will hold a conference call and webcast on Thursday, March 27, 2014 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning March 27, 2014 at 7:30 pm EDT until midnight March 30, 2014, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 12618657.
OTC Daily Alert Stock Watch - Capstone Therapeutics (OTCQB: CAPS)
WorldStockWire - Thu Aug 15, 9:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Capstone Therapeutics to Hold Quarterly Operating Update Conference Call
GlobeNewswire - Wed Aug 07, 1:16PM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , will hold a conference call and webcast on Wednesday, August 14, 2013 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning August 14, 2013 at 7:30 pm EDT until midnight August 17, 2013 and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 27383573.
Capstone Therapeutics Will Provide an Operating Update and Announces First Quarter 2013 Financial Results
GlobeNewswire - Wed May 15, 8:30AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , today will hold a conference call and webcast to provide an operating update and announced financial results for the first quarter 2013.
Capstone Therapeutics to Hold Operating Update Conference Call
GlobeNewswire - Wed May 08, 8:00AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , will hold a conference call and webcast on Wednesday, May 15, 2013 at 4:30 pm EDT. The call may be accessed at 877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying slides may be viewed by logging onto the Investors section of the Company's website, www.capstonethx.com. A replay will be available beginning May 15, 2013 at 7:30 pm EDT until midnight May 18, 2013 and may be accessed at 855-859-2056 (U.S.) or 404-537-3406 (outside U.S.) with conference ID 68894502.
Capstone Therapeutics Will Provide an Operating Update and Announces 2012 Financial Results
GlobeNewswire - Thu Mar 14, 7:15AM CDT
Capstone Therapeutics (OTCQB:CAPS); (the "Company" , today will hold a conference call and webcast to provide an operating update and 2012 financial results.
OTC Signal Daily Stock Watch - Capstone Therapeutics (CAPS)
WorldStockWire - Mon Dec 17, 10:45AM CST
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com